伏立诺他联合他克莫司/甲氨蝶呤预防清髓性预处理无关供者造血干细胞移植后GVHD
这项前瞻性2期研究纳入37例接受清髓性预处理、8/8-HLA相合无关供者造血干细胞移植的成人血液肿瘤患者,在标准他克莫司/甲氨蝶呤基础上加用伏立诺他(100 mg每日两次,移植前第10天至移植后第100天)。第100天2-4级急性GVHD累积发生率为22%,3-4级为8%;1年慢性GVHD、复发、非复发死亡、无GVHD无复发生存和总生存分别为29%、19%、16%、47%和76%。作者认为伏立诺他预防GVHD是有效策略,应在随机3期研究中确认。
要点
- 伏立诺他联合他克莫司/甲氨蝶呤在清髓性无关供者移植中安全可耐受。
- 第100天2-4级急性GVHD累积发生率为22%,3-4级为8%。
- 作者认为该策略有效,应在随机3期研究中确认。
核心结论
- 伏立诺他用于GVHD预防是有效策略,应在随机3期研究中确认。
研究设计与样本
- 前瞻性2期研究,纳入37例接受清髓性预处理、8/8-HLA相合无关供者造血干细胞移植的成人血液肿瘤患者。
- 研究设计提供80%把握度检测2-4级急性GVHD发生率50%降至目标28%的显著差异。
- 患者接受他克莫司和甲氨蝶呤GVHD预防,伏立诺他100 mg每日两次从移植前第10天用至移植后第100天。
- 中位年龄56岁(范围18-69岁),95%为急性髓系白血病或高危骨髓增生异常综合征。
主要发现
- 伏立诺他安全可耐受。
- 第100天2-4级急性GVHD累积发生率为22%,3-4级为8%。
- 慢性GVHD累积发生率为29%;1年复发、非复发死亡、无GVHD无复发生存和总生存分别为19%、16%、47%和76%。
- 相关分析显示,与未接受伏立诺他的类似治疗患者相比,伏立诺他治疗者移植后第30天外周血单个核细胞组蛋白H3乙酰化增强,白细胞介素6降低(P = .028),GVHD生物标志物Reg3降低(P = .041)、ST2降低(P = .002)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The oral histone deacetylase (HDAC) inhibitor (vorinostat) is safe and results in low incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning, related donor hematopoietic cell transplantation (HCT). However, its safety and efficacy in preventing acute GVHD in settings of heightened clinical risk that use myeloablative conditioning, unrelated donor (URD), and methotrexate are not known. We conducted a prospective, phase 2 study in this higher-risk setting. We enrolled 37 patients to provide 80% power to detect a significant difference in grade 2 to 4 acute GVHD of 50% compared with a reduction in target to 28%. Eligibility included adults with a hematological malignancy to receive myeloablative HCT from an available 8/8-HLA matched URD. Patients received GVHD prophylaxis with tacrolimus and methotrexate. Vorinostat (100 mg twice daily) was started on day -10 and continued through day +100 post-HCT. Median age was 56 years (range, 18-69 years), and 95% had acute myelogenous leukemia or high-risk myelodysplastic syndrome. Vorinostat was safe and tolerable. The cumulative incidence of grade 2 to 4 acute GVHD at day 100 was 22%, and for grade 3 to 4 it was 8%. The cumulative incidence of chronic GVHD was 29%; relapse, nonrelapse mortality, GVHD-free relapse-free survival, and overall survival at 1 year were 19%, 16%, 47%, and 76%, respectively. Correlative analyses showed enhanced histone (H3) acetylation in peripheral blood mononuclear cells and reduced interleukin 6 (P = .028) and GVHD biomarkers (Reg3, P = .041; ST2, P = .002) at day 30 post-HCT in vorinostat-treated subjects compared with similarly treated patients who did not receive vorinostat. Vorinostat for GVHD prevention is an effective strategy that should be confirmed in a randomized phase 3 study. This trial was registered at www.clinicaltrials.gov as #NCT01790568.
引用
- Choi SW, Braun T, Henig I, et al. Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. Blood. 2017. PMID: 28784598. doi:10.1182/blood-2017-06-790469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。